Analysis of Immunohistochemical Stain Usage in Different Pathology Practice Settings
|
|
- Darleen Ray
- 6 years ago
- Views:
Transcription
1 Anatomic Pathology / Immunohistochemistry Use by Practice Type Analysis of Immunohistochemical Stain Usage in Different Pathology Practice Settings Akeesha A. Shah, MD, Henry F. Frierson, Jr, MD, and Helen P. Cathro, MBChB Key Words: Immunohistochemistry; Academic; Private practice; Commercial Abstract This study compares the use of immunohistochemistry (IHC) for diagnosing carcinoma in private practice and commercial settings with use in a single academic center. H&E-stained slides and IHC stains, when present, of recently diagnosed carcinomas (n = 200) from patients referred to our institution for treatment were reviewed by a resident and midand senior-level pathologists. Diagnostic agreement between academic and referral pathologists was 98%; the former group used IHC stains in 11% and the latter in 26% of cases (P <.0001). Pathologists from commercial laboratories (12% of referrals) used IHC in 38% of cases, whereas private/hospital-based community laboratories (86% of referrals) used them in 24%. The average number of stains ordered per case was similar among all groups. We suggest that the use of IHC may reflect both the degree of experience of the pathologist and the pathology practice setting. For more than 25 years, immunohistochemistry (IHC) has greatly assisted surgical pathologists in the diagnosis of neoplastic diseases. Currently, IHC has a wide variety of uses, including, but not limited to, confirmation of diagnosis, determination of the primary site of origin for metastatic tumors, classification of neoplasms, use as a prognostic and predictive biomarker, and identification of infectious organisms. Residents at all levels of training in surgical pathology are exposed to IHC and must become proficient in its application, interpretation, and limitations. With its proliferation in pathology practice settings of all types, the temptation to overuse it continues. IHC should, of course, complement and not supersede information gleaned from the clinical context and the H&E-stained morphologic appearance. The pathology literature is inundated with articles that address the usefulness of diagnostic IHC algorithms and panels for tumor classification. However, there is a paucity of studies examining the patterns of usage of IHC among pathologists, possibly because of the inherent bias likely to be present in the study design. Despite this limitation, our anecdotal experience is that IHC usage varies among practice types as well as according to the pathologist s level of experience. Hence, we examined the application of IHC in a group of patients with carcinomas referred to the University of Virginia (UVA) Health System (Charlottesville, VA) for treatment and compared its frequency of use among different practice settings and experience level among the authors of this study. Materials and Methods Two hundred nearly consecutive cases from October 2010 to October 2011 were selected for review from the files Downloaded from Am J Clin Pathol 2012;138:
2 Shah et al / Immunohistochemistry Use by Practice Type of the Department of Pathology at UVA. The cases comprised carcinomas from patients chiefly referred to our institution for definitive treatment and consisted mainly of biopsy specimens that yielded the initial diagnosis of invasive cancer. Patients with a prior diagnosis of cancer were excluded from this study. Hematopathology, neuropathology, renal pathology, and cytopathology cases were also excluded. The cases were blindly and individually reviewed by each of the 3 authors. These study pathologists represented a midlevel resident and midlevel and senior-level faculty pathologists. In addition to the H&E stains, the study pathologists were provided with the age and sex of each patient, the location of the biopsy specimen, and a brief clinical history taken from the referring institution s surgical pathology report. Study pathologists recorded their diagnosis based solely on review of the H&E-stained sections. They had no prior knowledge of any previously performed IHC stains. After a review of the H&E slides, study pathologists recorded the IHC stains they would have ordered to aid their diagnosis as if they were signing out the case as the primary pathologist. Only after recording their diagnosis were they given access to the IHC stains or results of the IHC stains that had been previously performed, either by the referring institution or by the UVA pathologist who had initially reviewed and signed out the case. It should be noted that in those instances in which the study pathologist would have required additional IHC stains, they were not actually performed because the study was carried out retrospectively and tissue specimens were not available. IHC stains used for prognostication or in guiding treatment, such as estrogen and progesterone receptors in breast carcinoma, were not recorded. Referring institutions were categorized as commercial or private, including hospital-based, the former being defined as those whose pathologists had no hospital affiliation. All commercial pathology laboratories included in this report had operations in multiple states. Using the referring institution s surgical pathology report, the diagnoses and number of IHC stains performed in each case, as well as the type of IHC stain performed by the primary pathologists, were recorded after the study pathologists had made their interpretations. To help overcome the inherent bias in the study, namely, that all the included cases were known by the study pathologists to likely represent carcinomas, 200 consecutive sitematched biopsy specimens with a first-time carcinoma diagnosis made at our institution from May 2009 to November 2011 were selected as control cases. All were of a similar level of complexity as the study cases. These cases were not signed out by either of the study pathologists. The pathologists signing out these cases were all surgical pathology faculty members at UVA and are referred to as control pathologists throughout this article. It should be mentioned that UVA does not have a specialty sign out system, but rather all surgical pathologists sign out all types of cases except for complex hematopathology, dermatopathology, neuropathology, and renal pathology cases. All the faculty members have areas of special interest in tumor pathology, and interdepartmental consultations are frequent. The level of experience of the other faculty members is summarized as follows: senior (n = 5) and midlevel (n = 4), with senior pathologists defined as those in practice for more than 10 years. The diagnosis of the control pathologists as well as the number of IHC stains used were recorded. Diagnostic agreement, the average number of cases for which IHC stains were used, the average number of IHC stains per case, as well as the average number of IHC stains used with respect to organ system, were compared among study pathologists, referring pathologists, and control pathologists. P values were obtained using the Fisher exact test, with P <.05 considered significant (Graphpad Software, La Jolla, CA). Results Anatomic sites for the 200 referral cases included prostate (41), endometrium (33), other genitourinary (29), gastrointestinal and hepatobiliary tracts (27), lung (21), head and neck, (19), breast (16), other gynecologic (11), and bone/soft tissue (3) Figure 1. Of the 200 cases, 172 were from private 19 (9.5%) 21 (10.5%) 16 (8.0%) 11 (5.5%) 27 (13.5%) 3 (1.5%) 41 (20.5%) 29 (14.5%) 33 (16.5%) Prostate Endometrium Other genitourinary Gastrointestinal and hepatobiliary Lung Head and neck Breast Other gynecologic Bone and soft tissue Figure 1 Distribution of organ systems among the 200 referral/control cases. 832 Am J Clin Pathol 2012;138: Downloaded 832 from
3 Anatomic Pathology / Original Article practice/hospital-based pathology groups (n = 55), 24 were from commercial groups (n = 12), and 4 were from academic medical centers (n = 4). Overall diagnostic agreement between study and referring pathologists was 98%. Discrepant diagnoses were found in 4 cases, each of which was of genitourinary origin. One case was interpreted as a poorly differentiated carcinoma by the referring pathologist and as clear cell renal cell carcinoma by the study pathologists. The second case was diagnosed as a condyloma by the referring pathologists and interpreted as squamous cell carcinoma by study pathologists. The third case was diagnosed as an adenocarcinoma by referring pathologists and interpreted as urothelial carcinoma by study pathologists. The fourth case was diagnosed as chromophobe carcinoma by referring pathologists and interpreted as an oncocytoma by study pathologists. Where there was disagreement among study pathologists, a consensus was reached in all cases when 2 of the 3 study pathologists concurred. IHC stains were/would have been used by both referring and study pathologists in 3 of the 4 cases. Referring and study pathologists used IHC stains in 26% and 11% of total cases, respectively (P <.0001) Table 1. Pathologists from commercial laboratories (12% of referral cases) used IHC in 38% of cases, whereas those from private or hospital-based community laboratories (86% of referral cases) used IHC in 24% of cases. The total number of cases in which IHC was used varied among study pathologists to a smaller degree; the senior pathologist used stains in 6% of cases, the midlevel pathologist in 14% of cases, and the resident in 10% of cases. The greatest differences between referring and study pathologists in IHC usage were seen for the following sites: lung (71% vs 38%; P =.062), prostate (27% vs 5%; P =.013), breast (31% vs 13%; P = not significant [NS]), and other gynecologic (27% vs 9%; P = NS). When IHC stains were performed, the average number of stains used per case by pathologists from private groups Table 1 Comparison of the Number of Immunohistochemistry Cases Between Referring and Study Pathologists * No. of Cases With Immunohistochemistry Referring Study Organ System (n = 200) Pathologists Pathologists P Value Prostate (n = 41) 11 (27) 2 (5).013 Endometrium (n = 33) 2 (6) Other genitourinary (n = 29) 6 (21) 3 (10).47 Gastrointestinal and 5 (19) 1 (4).192 hepatobiliary (n = 27) Lung (n = 21) 15 (71) 8 (38).062 Head and neck (n = 19) 4 (21) 3 (16) 1.00 Breast (n = 16) 5 (31) 2 (13).394 Other gynecologic (n = 11) 3 (27) 1 (9).587 Bone and soft tissue (n = 3) 1 (33) 1 (33) 1.00 Total cases 52 (26) 21 (11) <.0001 * Data are given as number (percentage) unless otherwise indicated. was 4, whereas those in commercial laboratories as well as the study pathologists used an average of 3 stains per case. The average number of stains used per case did not vary with experience level among study pathologists; all used an average of 3 stains per case. Excluding bone/soft tissue, which had too few cases for analysis, the organ system with the highest average number of stains per referral case was head and neck, with an average of 6 IHC stains per case; study pathologists used an average of 3 stains per case. For 4 other organ systems, private pathologists used more stains on average than study pathologists: 5 vs 2 IHC stains used per lung case; 4 vs 2 stains per gastrointestinal/hepatobiliary case; 3 vs 2 stains per gynecologic case; and 3 vs 1 stain per breast case. The majority of commercial cases were prostate biopsies, and these pathologists used a broader range of stains per case than either private or study pathologists Table 2. For the site-matched control group, the overall IHC rate of usage was 13%, which is not statistically different from Table 2 Immunohistochemistry Ordering Practices Among Commercial, Private, and Study Pathologists Distributed by Organ System Commercial Pathologists Private Pathologists Study Pathologists No. of Cases Mean No. of No. of Cases Mean No. of No. of Cases Mean No. of Organ System With IHC Stains (Range) With IHC Stains (Range) With IHC Stains (Range) Prostate 6 3 (1-7) 5 2 (1-4) 2 2 (2-5) Endometrium 1 1 (NA) 1 5 (NA) 0 NA Other genitourinary 0 NA 6 3 (1-4) 3 3 (3-4) Gastrointestinal and 0 NA 5 4 (1-7) 1 2 (2-3) hepatobiliary Lung 0 NA 15 5 (1-9) 8 2 (2-4) Head and neck 0 NA 3 6 (3-13) 3 3 (1-7) Breast 1 1 (NA) 4 3 (1-7) 2 1 (NA) Other gynecologic 1 6 (NA) 2 3 (1-4) 1 2 (NA) Bone and soft tissue 0 NA (2-5) IHC, immunohistochemistry; NA, not available. Downloaded from Am J Clin Pathol 2012;138:
4 Shah et al / Immunohistochemistry Use by Practice Type study pathologists at 11% (P =.64). With the exclusion of bone/soft tissue, the lung was the organ with the greatest average usage of IHC for control pathologists, as well as for referral and study pathologists. In contrast to referring and study pathologists, the control pathologists used more IHC stains for endometrial cases (6% and 0% vs 18%, respectively) Table 3. The top 10 IHC stains used by referral pathologists were thyroid transcription factor 1 (TTF-1), prostatic intraepithelial neoplasia 4 (PIN4) cocktail, and cytokeratin 7 (CK7) (each used at the same frequency), CK5/6, and cytokeratin cocktail, and then CK20, p63, synaptophysin, chromogranin, and highmolecular-weight kininogen (HMWK) Table 4. Discussion Before IHC, which has been performed in diagnostic pathology for nearly 3 decades, a number of other techniques were used to augment basic H&E histology. The Society for Histochemistry was founded in Germany in 1952, and American pathologists readily embraced new histochemical stains in the practice of diagnostic pathology, as documented by the leading pathology textbooks of the time. 1,2 Transmission Table 3 Control Pathologists Use of Immunohistochemistry Organ System (n = 200) Prostate (n = 41) 7 (17) Endometrium (n = 33) 6 (18) Other genitourinary (n = 29) 0 Gastrointestinal and hepatobiliary (n = 27) 5 (19) Lung (n = 21) 5 (24) Head and neck (n = 19) 0 Breast (n = 16) 0 Other gynecologic (n = 11) 1 (9) Bone and soft tissue (n = 3) 1 (33) Total cases 25 (13) No. (%) of Cases With Immunohistochemistry electron microscopy (EM) was the next tool used to aid the histopathologist, but its widespread dissemination was limited by cost; it was primarily used in academic medical centers and Veterans Affairs hospitals. 3 Although few general surgical pathologists currently use EM on a regular basis for tumor examination, it has been pointed out that depending on the tumor type this method may be more cost-effective than a panel of IHC stains. 4 Similarly, immunofluorescence microscopy is used by few pathologists, mainly renal and dermatopathologists, in part because of the requirement for an immunofluorescence microscope. In situ hybridization microscopy is another spinoff from histochemistry that combines molecular analysis with slide-based techniques. Beginning in the 1980s, IHC quickly supplanted histochemistry, being particularly attractive because of its ability to more accurately suggest the specific type or the anatomic site of origin for various cancers. 5-9 IHC can be performed rapidly without expensive specialized equipment and is increasingly being automated. Once the pattern of staining in control tissue is ascertained, IHC is relatively straightforward to interpret. Unfortunately, it can easily be abused, both by over- and misutilization. Except in selected circumstances, the use of a single IHC stain is not optimal, with logical IHC algorithms for particular differential diagnoses being far more discriminating and accurate. Clinical demand for rapid turnaround of cases has no doubt contributed to the problem of overutilization, with pathologists unwilling to hold a case for a second round of IHC. The use of IHC has become so prevalent that some pathologists may spend less time examining the H&E stain in favor of evaluating the IHC results. Other problems with IHC relate to quality of staining, antibody sensitivity and specificity, interpretation, and their regulation Potential conflict of interest with regard to ordering IHC stains is likely to receive increasing scrutiny in this age of Medicare cost rationalization. The type of IHC stain as well as the number used may also affect costs, eg, IHC cocktails processed using separate vials for each antibody can be charged as multiple IHC stains, despite being performed on a single Table 4 The 10 Most Used Immunohistochemical Stains by Organ Site Organ System TTF-1 CK7 PIN4 CK5/6 CK CK20 p63 SYN CHR HMWK Prostate Endometrium 1 1 Other Genitourinary Gastrointestinal and hepatobiliary Lung Head and neck Breast 1 Other Gynecologic Bone/soft tissue 1 Total CHR, chromogranin; CK, cytokeratin; HMWK, high-molecular-weight kininogen; PIN4, prostatic intraepithelial neoplasia 4; SYN, synaptophysin; TTF-1, thyroid transcription factor Am J Clin Pathol 2012;138: Downloaded 834 from
5 Anatomic Pathology / Original Article slide, depending on the payor. IHC cocktails processed using multiple antibodies per single vial can only be charged once. Very few studies have addressed the overall patterns of IHC usage, in part because of the difficulty of performing such studies without bias. One study addressing second opinion surgical pathology review found that repeating IHC stains and adding new ones to the panel resulted in a change in diagnosis in 18.3% of cases for which IHC was performed. 13 These authors concluded that repeating or performing IHC in cancer cases referred to a tertiary care center for treatment was important for patient care. An analysis of the costeffectiveness of IHC in 1998 found a usage rate of 6% at a general hospital, which contrasts with the 26% rate by referral pathologists in our study. 14 This study reached the conclusion that IHC is extremely cost-effective; however, the analytic algorithm was based on the premise that the correct diagnosis could not have been reached without IHC. To our knowledge, the current study is the first of its kind to examine IHC on the basis of pathology practice setting as well as the level of experience of the pathologist. We found a significant difference between referring and study pathologists in the frequency with which IHC was performed, with referring pathologists using IHC in more cases than study pathologists (26% vs 11%; P <.0001). Pathologists from commercial laboratories used IHC more often than pathologists from private laboratories (38% vs 24%). Most of the cases sent from commercial laboratories consisted of prostate specimens, with the PIN4 cocktail being the most commonly ordered IHC stain. In private practice laboratories, the lung was the organ site with the highest number of IHC stains; TTF-1 was the most commonly used stain. The increased use of TTF-1, p63, and CK5/6 is likely caused by the perceived need to more accurately classify lung cancers, as targeted therapies for specific histologic types are now available. Despite the differences among commercial, private, and study pathologists in total number of cases in which IHC was performed, no significant difference was found in the average number of IHC stains used per case. Private groups used an average of 4 stains per case, whereas commercial and study pathologists used 3 per case. Among the study pathologists, no statistically significant difference was seen in the average number of IHC stains used per case based on level of experience. However, overall, the senior pathologist used IHC in fewer cases (6%) than both the midlevel pathologist (14%) and the midlevel resident (10%). Senior pathologists were trained during an era in which H&E histology was emphasized, whereas midlevel pathologists are likely to be more dependent on IHC. The resident s lower rate of IHC usage compared with the midlevel pathologist may be explained partly by uncertainty about the correct use of IHC. Other pathologists in our department used IHC no more than study pathologists except for endometrial cases; this finding is most likely because one of the faculty pathologists recently published a study on using IHC in gynecologic pathology, thus stimulating an awareness of its potential usefulness in this setting. The top 10 IHC stains used by referring pathologists, in descending order, were as follows: TTF-1, CK7, and PIN4 (each used at the same frequency), followed by CK5/6 and pankeratin, and then CK20, p63, synaptophysin, chromogranin, and HMWK. In our opinion, CK7 and CK20 are among the most commonly overused IHC stains, especially as there are more tumor-specific reagents that yield fruitful information. Our study has several biases and limitations. An important bias was that the cases analyzed were all referral cases of known first-time diagnoses of carcinoma. Despite this knowledge, study pathologists attempted to approach the cases as though they were being diagnosed for the first time and as though they were not necessarily malignant. Cases were primarily biopsies that were not particularly diagnostically complex but represented routine cancer diagnoses that would be made on a daily basis. Additional limitations were that the cases selected did not represent all organ sites; also all of the sites present in this study were not equally represented. Our study was relatively small (200 referral cases), and a larger study, especially one in which the case mix differed from ours, might show additional or contradictory findings. In conclusion, although diagnostic agreement among pathologists in several practice settings was high, referral pathologists used IHC stains in a higher proportion of cases than those at our academic medical center. Interestingly, the average number of stains used per case was very similar among pathologists of the 3 practice types. An analysis of the particular stains suggests that the increase in targeted therapy for lung carcinoma, in particular, may be driving some usage patterns. The pattern for IHC usage may also reflect the degree of experience of the individual pathologist. From the Department of Pathology, University of Virginia Health System, Charlottesville, VA. Support for this study was provided by the Department of Pathology at the University of Virginia Health System. This study was presented in part at the 2012 Annual Meeting of the United States and Canadian Academy of Pathology Meeting; March 2012; Vancouver, Canada. Address reprint requests to Dr. Cathro: Department of Pathology, University of Virginia Health System, PO Box , Charlottesville, VA 22908; hpc4f@virginia.edu. References 1. Gossner W. A brief history of the Society for Histochemistry; its founders, its mission and the first 50 years. Histochem Cell Biol. 2002;118: Downloaded from Am J Clin Pathol 2012;138:
6 Shah et al / Immunohistochemistry Use by Practice Type 2. Wick MR. Histochemistry as a tool in morphological analysis: a historical review. Ann Diagn Pathol. 2012;16: Williams MJ, Uzman BG. Uses and contributions of diagnostic electron-microscopy in surgical pathology - a study of 20 Veterans Administration hospitals. Hum Pathol. 1984;15: King JA. Role of transmission electron microscopy in cancer diagnosis and research. Microsc Microanal. 2007;13: Brandtzaeg P. The increasing power of immunohistochemistry and immunocytochemistry. J Immunol Methods. 1998;216: Coleman R. The impact of histochemistry: a historical perspective. Acta Histochem. 2000;102: Jaffer S, Bleiweiss IJ. Beyond hematoxylin and eosin: the role of immunohistochemistry in surgical pathology. Cancer Invest. 2004;22: Stoward PJ, Nakae Y, Van Noorden CJF. The everchanging advances in enzyme histochemistry, Eur J Histochem. 1998;42: Teruya-Feldstein J. The immunohistochemistry laboratory: looking at molecules and preparing for tomorrow. Arch Pathol Lab Med. 2010;134: Cattoretti G. Standardization and reproducibility in diagnostic immunohistochemistry: reply. Hum Pathol. 1994;25: Dacic S, Yousem SA. Molecular testing in lung carcinoma: quo vadis? Am J Clin Pathol. 2010;134: True LD. Quality control in molecular immunohistochemistry. Histochem Cell Biol. 2008;130: Wetherington RW, Cooper HS, Al-Saleem T, et al. Clinical significance of performing immunohistochemistry on cases with a previous diagnosis of cancer coming to a national comprehensive cancer center for treatment or second opinion. Am J Surg Pathol. 2002;26: Raab SS. The cost-effectiveness of immunohistochemistry. Arch Pathol Lab Med. 2000;124: Am J Clin Pathol 2012;138: Downloaded 836 from
Cleveland Clinic Laboratories. Anatomic Pathology
Cleveland Clinic Laboratories Anatomic Pathology OUR MISSION Cleveland Clinic Laboratories contributes to excellent patient care by providing high-quality, comprehensive laboratory testing and patient-focused
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationApplying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice
Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice Dr. Gregory Flynn CEO, Institute for Quality Management in Healthcare Managing Director, Quality Management
More informationDepartment of Pathology Presentation to Dr. Garcia
Department of Pathology Presentation to Dr. Garcia Clinical Service Anatomic Pathology September 8, 2014 Presented by Dr. Erika Bracamonte Head of Anatomic Pathology 0 Anatomic Pathology Divisions Surgical
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationPreface to the Second Edition
Preface to the Second Edition This second edition of Diagnosis of Endometrial Biopsies and Curettings: A Practical Approach follows a number of favorable comments we received about the first edition. As
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationDiagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018
Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018 Dr. Tzahi Neuman Dep.Of Pathology Hadassah Medical Center Jerusalem, Israel, (tneuman@hadassah.org.il) Disclosure: 1 no conflicts of
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationObservership Program Anatomical Pathology
Observership Program Anatomical Pathology Pathology is the study and diagnosis of diseases through examination of organs, tissues, cells and bodily fluids. Pathology is a unique medical specialty in that
More informationQuality Indicators - Anatomic Pathology- HSC/STC Jul-Sep 2 nd Qtr. Apr-Jun 1 st Qtr
Eastern Health Volume 86 Page 001 CIHRT Exhibit P-3595 Page 1 INDICATOR Financial Overtime Hours / FTE Workload Increase - FTE equivalent Workload Quality Indicators - Anatomic Pathology- HSC/STC TOTAL
More informationDigital Pathology - moving on after implementation. Catarina Eloy, MD, PhD
Digital Pathology - moving on after implementation Catarina Eloy, MD, PhD Catarina Eloy, MD, PhD No conflict of interests to declare Pathology challenges today Maintaining high quality students interested
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More information117 Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice. Gregory Flynn MD
117 Applying Risk Management Principles to QA in Surgical Pathology: From Principles to Practice Gregory Flynn MD 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY 33 W. Monroe,
More informationQuality assurance and quality control in pathology in breast disease centers
Quality assurance and quality control in pathology in breast disease centers Judith Sandbank M.D. Pathology Assaf-Harofeh Medical Center ISRAEL jsandbank@asaf.health.gov.il 1 st IBDC, 28 th January, 2011
More informationDifferential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
More information2018 Surgical Pathology Update: Diagnostic Pearls for the Practicing Pathologist - Volume II
Release Date: January 1, 15.25 AMA PRA Category 1 Credit(s) TM About This CME Teaching Activity This CME Activity is designed to provide a comprehensive review of soft tissue, gastrointestinal, genitourinary,
More informationImmunohistochemical Profile of Lung Tumors in Image Guided Biopsies
Original Article DOI: 10.21276/APALM.1342 Immunohistochemical Profile of Lung Tumors in Image Guided Biopsies T. Pavithra 1 *, A. Dhanalakshmi 1, C. Lalitha 1, K.B. Lavanya 1 and S. Shifa 2 Department
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationQuality, Patient Safety and Error Reduction in Cytopathology
CAP Companion Society Meeting at USCAP 2009 Quality Assurance, Error Reduction, and Patient Safety in Anatomic Pathology Quality, Patient Safety and Error Reduction in Cytopathology Jan F. Silverman, MD,
More informationRitu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL
Ritu Nayar, MD Professor and Vice Chair of Pathology Northwestern University, Feinberg School of Medicine Chicago, IL email: r-nayar@northwestern.edu Nothing to disclose College of American Pathologists
More information1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationGYNECOLOGICAL PATHOLOGY FELLOWSHIP PROGRAM
GYNECOLOGICAL PATHOLOGY FELLOWSHIP PROGRAM The Department of Pathology and Laboratory Medicine University of Calgary, Faculty of Medicine Calgary Health Region and Calgary Laboratory Services Calgary,
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationSingle and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
More informationHistological Typing Of Cancer And Precancer Of The Oral Mucosa
Histological Typing Of Cancer And Precancer Of The Oral Mucosa 1 / 7 2 / 7 3 / 7 Histological Typing Of Cancer And Within the last decade, histologic grading has become widely accepted as a powerful indicator
More informationACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016
Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES
More informationAmerican Journal of. Medical Case Reports. CAM5.2 Expression in Metastatic Tumours of CNS: A Diagnostic Tool
American Journal of American Journals of Medical Case Reports http://ivyunion.org/index.php/ajmcr/index Medical Case Reports Mathur SK et al. American Journal of Medical Case Reports 2014, 2:1-8 Vol 2,
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationMesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016
Mesothelioma: diagnostic challenges from a pathological perspective Naseema Vorajee August 2016 Naseema.vorajee@nhls.ac.za Pleural diseases (whether neoplastic, reactive or infective) may have similar
More informationUW Medicine Neuropathology
Neuropathology in Patient Care Surgical Neuropathology is that subspecialty of pathology that provides diagnoses on biopsies from the brain, spinal cord, skeletal muscle, peripheral nerve, and eye. In
More informationINTRODUCTION TO PATHOLOGY
INTRODUCTION TO PATHOLOGY The literal translation of the word pathology is the study (logos) of suffering (pathos). It is a discipline that bridges clinical practice and basic sciences. Pathology is concerned
More informationHuman Papillomavirus Testing in Head and Neck Carcinomas
Human Papillomavirus Testing in Head and Neck Carcinomas Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine 12/18/2017 Overview
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationPathology Student Interest Group. Sponsored by the College of American Pathologists
Pathology Student Interest Group Sponsored by the College of American Pathologists Pathology Right Now, A Pathologist Somewhere Is. Evaluating Surgical Specimens Diagnosis and Staging of Cancer Adequacy
More informationANATOMICAL PATHOLOGY TARIFF
ANATOMICAL PATHOLOGY TARIFF A GUIDE TO UTILISATION. The following guidelines have been agreed by consensus of Anatomical Pathologists who are members of the Anatomical Pathologist s Group, or the National
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationHistotechnological problems in dermatopathology and their possible consequences
Histotechnological problems in dermatopathology and their possible consequences Zsolt B. Argenyi, M.D. Professor of Pathology & Dermatology Director of Dermatopathology University of Washington, Seattle,
More informationRepeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results
Anatomic Pathology / REPEAT THYROID FINE-NEEDLE ASPIRATION Repeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results Melina B. Flanagan, MD, MSPH, 1 N. Paul Ohori,
More informationHyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000
Hyperchromatic Crowded Groups: What is Your Diagnosis? Session 3000 Thomas A. Bonfiglio, M.D. Professor Emeritus, Pathology and Laboratory Medicine University of Rochester Disclosures In the past 12 months,
More informationBreast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationInterpretive Diagnostic Error Reduction in Surgical Pathology and Cytology
Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology Guideline from the College of American Pathologists (CAP) Pathology and Laboratory Quality Center and the Association of Directors
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationImmunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD
Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor
More informationUW Medicine Neuropathology
Neuropathology in Patient Care Surgical Neuropathology is that subspecialty of pathology that provides diagnoses on biopsies from the brain, spinal cord, skeletal muscle, peripheral nerve, and eye. In
More informationCase history: Figure 1. H&E, 5x. Figure 2. H&E, 20x.
1 Case history: A 49 year-old female presented with a 5 year history of chronic anal fissure. The patient s past medical history is otherwise unremarkable. On digital rectal examination there was a very
More informationDermatopathology Training Standards
Dermatopathology Training Standards Tammie Ferringer, MD Section Head and Fellowship Director Dermatopathology Depts of Dermatology and Pathology tferringer@geisinger.edu I do not have any relevant relationships
More informationGOALS AND OBJECTIVES BREAST PATHOLOGY
GOALS AND OBJECTIVES BREAST PATHOLOGY LEVEL: PGY2, PGY3, PGY5 A number of these rotations are introductory in nature, as they are major subspecialties, and are followed by two more blocks in PGY-3, during
More informationThe TNM classification is a worldwide benchmark for reporting the
1 COMMENTARY The Process for Continuous Improvement of the TNM Classification Mary K. Gospodarowicz, M.D. 1 Daniel Miller, M.D., M.P.H. 2 Patti A. Groome, M.Sc., Ph.D. 3 Frederick L. Greene, M.D. 4 Pamela
More informationCytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami
Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics Mercè Jordà, University of Miami Mortality Lung cancer is the most frequent cause of cancer incidence and mortality
More informationACCURACY OF IMMUNOHISTOCHEMISTRY IN EVALUATION
POL J PATHOL 2011; 2: 95-100 ACCURACY OF IMMUNOHISTOCHEMISTRY IN EVALUATION OF MALIGNANT PLEURAL AND PERITONEAL EFFUSIONS FERESHTEH ENSANI, FARNAZ NEMATIZADEH, GITI IRVANLOU Department of Cytology, Cancer
More informationThe clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
More informationImmunohistochemistry on Fluid Specimens: Technical Considerations
Immunohistochemistry on Fluid Specimens: Technical Considerations Blake Gilks Dept of Pathology University of British Columbia, Vancouver, BC, Canada Disclosures None Learning Objectives At the end of
More informationSynonyms. Nephrogenic metaplasia Mesonephric adenoma
Nephrogenic Adenoma Synonyms Nephrogenic metaplasia Mesonephric adenoma Definition Benign epithelial lesion of urinary tract with tubular, glandular, papillary growth pattern Most frequently in the urinary
More informationOverview of Indeterminate Cytology
83 rd Annual Meeting American Thyroid Association Overview of Indeterminate Cytology Scott Boerner MD FRCPC Head Cytopathology, University Health Network University of Toronto DISCLOSURE Nothing to disclose
More informationUpdate on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center
Update on Thyroid FNA The Bethesda System Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center Thyroid Nodules Frequent occurrence Palpable: 4-7% of adults Ultrasound: 10-31% Majority benign
More informationNPQR 2018 Qualified Clinical Data Registry (QCDR) Measures 21_18247_LS.
NPQR 2018 Qualified Clinical Data Registry (QCDR) Measures 21_18247_LS MEASURE ID: NPQR1 MEASURE TITLE: Notification to the Ordering Provider Requesting Myoglobin or CK-MB in the Diagnosis of Suspected
More informationGuideline for the Handling of Pathology Lung Tissue Specimens
Guideline for the Handling of Pathology Lung Tissue Specimens Version Date Summary of Change/Process 0.1 29.06.11 Produced by Simon Trotter and circulated to Lung Network Site Specific Group for reviewing
More informationQ1 Where is your primary practice?
Q1 Where is your primary practice? Answered: 120 Skipped: 0 United States Canada Currently, I don't practice Other (please specify) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% ANSWER CHOICES United States
More informationCAP Companion Meeting at USCAP Quality and Patient Safety in Anatomic Pathology: Practical Solutions. Surgical Pathology
CAP Companion Meeting at USCAP 2010 Quality and Patient Safety in Anatomic Pathology: Practical Solutions Directed Peer Review in Surgical Pathology Stephen S. Raab, MD University of Colorado Denver 2010
More informationRadiology Pathology Conference
Radiology Pathology Conference Sharlin Johnykutty,, MD, Cytopathology Fellow Sara Majewski, MD, Radiology Resident Friday, August 28, 2009 Presentation material is for education purposes only. All rights
More informationFor additional information on meeting the criteria for Mohs, see Appendix 2.
Position Statement on Appropriate Uses of Paraffin Sections in Association (Approved by the Board of Directors: August 1, 2011; Revised November 5, 2011; Revised August 9, 2014) According to AMA/CPT, Mohs
More informationGuideline. Associated Documents ASCO CAP 2018 GUIDELINES and SUPPLEMENTS -
Guideline Subject: ASCO CAP 2018 HER2 Testing for Breast Cancer Guidelines - Recommendations for Practice in Australasia Approval Date: December 2018 Review Date: December 2022 Review By: HER2 testing
More informationReview of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo
Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso
More informationReviewer's report. Version: 1 Date: 24 May Reviewer: Cathy Moelans. Reviewer's report:
Reviewer's report Title: Validation of HER2 testing with core needle biopsy specimens from primary breast cancers in terms of interobserver reproducibility and concordance with surgically resected specimens
More informationUpdate on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
More informationDisclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1
Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013
More informationCase 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:
Case 18 M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is: A. Pilomatrical carcinoma B. Adnexal carcinoma NOS C. Metastatic squamous cell carcinoma D.Primary squamous cell carcinoma
More informationA re-audit of Prostate biopsies from January to December 2010 and 2013.
A re-audit of Prostate biopsies from January to December 2010 and 2013. Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees Stockton on Tees. Objectives To assess and compare
More informationCatholic University of Louvain, St - Luc University Hospital Head and Neck Oncology Programme. Anatomopathology. Pathology 1 Sept.
Anatomopathology Pathology 1 Anatomopathology Biopsies Frozen section Surgical specimen Peculiarities for various tumor site References Pathology 2 Biopsies Minimum data, which should be given by the pathologist
More informationTEST MENU BY SPECIALTY
1 TEST MENU BY SPECIALTY Breast Pathology Surgical excisions, needle core biopsies, and plastic surgery accepted from all sites Assessment of margins Axillary lymph node dissections Sentinel lymph nodes
More informationCOMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME
COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME Maria Lunardi MD Anatomic Pathology Fracastoro Hospital San Bonifacio, Verona -Italy HER2-neu
More informationNEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
More informationCase year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationFormat Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te
Florida Cancer Data System International Classification of Diseases for Oncology ICD-O-3 1 Basic Concepts Primary Site/Topography Histology/Morphology Behavior Grade/Immunophenotype 2 ICD-O 3 Structure/Format
More informationCase 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More informationNeuroendocrine neoplasms of the lung
Neuroendocrine neoplasms of the lung M Papotti, L Righi, & M Volante University of Turin at San Luigi Hospital TORINO NETs OF THE LUNG Menu - Spectrum of NE lung tumors - CARCINOID TUMORS - SCLC /LCNEC
More informationProstate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue
IHC Interpretation: General Principles (1) Prostate Immunohistochemistry Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Must be aware of staining pattern of antibody in the relevant tissue Nuclear/cytoplasmic/membranous
More informationUSCAP 2012: Companion Meeting of the AAOOP. Update on lacrimal gland neoplasms: Molecular pathology of interest
USCAP 2012: Companion Meeting of the AAOOP Vancouver BC, Canada, March 17, 2012 Update on lacrimal gland neoplasms: Molecular pathology of interest Valerie A. White MD, MHSc, FRCPC Department of Pathology
More informationWT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic Adenocarcinoma to Body Fluids
Anatomic Pathology / WT1, ESTROGEN RECEPTOR, AND PROGESTERONE RECEPTOR IN CYTOLOGY OF BODY FLUIDS WT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic
More informationQuantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer
Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine
More informationCutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationA 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.
November 2015 Case of the Month A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy. Contributed by: Rasha Salama, M.D., IU Department of Pathology and Laboratory Medicine
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Biopsy diagnosis of renal tumors. Current applications Ondřej Hes Department of Pathology Charles University and University Hospital Plzeň Czech Republic Dealing
More informationNeuroendocrine Lung Tumors Myers
Diagnosis and Classification of Neuroendocrine Lung Tumors Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of Michigan, Ann Arbor, MI myerjeff@umich.edu
More informationLiver Specialty Evening Conference. Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle
Liver Specialty Evening Conference Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle Case History A 65 year-old man presents with abdominal
More informationMorphologic Criteria of Invasive Colonic Adenocarcinoma on Biopsy Specimens
ISPUB.COM The Internet Journal of Pathology Volume 12 Number 1 Morphologic Criteria of Invasive Colonic Adenocarcinoma on Biopsy Specimens C Rose, H Wu Citation C Rose, H Wu.. The Internet Journal of Pathology.
More informationchapter 4. The effect of oncogenic HPV on transformation zone epithelium
chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More informationLessons learned in the use of digital imaging at Memorial Sloan Kettering Cancer Center
Lessons learned in the use of digital imaging at Memorial Sloan Kettering Cancer Center Executive War College May 3, 2018 Victor E. Reuter, M.D. Vice-Chair, Department of Pathology Medical Director, Warren
More informationDIRECTED WORKPLACE-BASED ASSESSMENTS BY STAGES OF TRAINING AND OPTIONAL PACKAGES
DIRECTED WORKPLACE-BASED ASSESSMENTS BY STAGES OF TRAINING AND OPTIONAL PACKAGES The following are lists of workplace-based assessments, from which should be selected appropriate examples to make up the
More informationAddendum report coding for the National Quality Improvement Programme in Histopathology: a multi-institutional audit
Addendum report coding for the National Quality Improvement Programme in Histopathology: a multi-institutional audit S. Mahon 1,3, D. Catargiu 2, S. Phelan 2, S. Crowther 3, N. Swan 1. St. Vincent s University
More informationInsulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens
Insulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens Kartik Viswanathan, M.D., Ph.D New York Presbyterian - Weill
More informationGeisinger Clinic Annual Progress Report: 2011 Nonformula Grant
Geisinger Clinic Annual Progress Report: 2011 Nonformula Grant Reporting Period July 1, 2012 June 30, 2013 Nonformula Grant Overview The Geisinger Clinic received $1,000,000 in nonformula funds for the
More informationGOALS AND OBJECTIVES CYTOPATHOLOGY
GOALS AND OBJECTIVES CYTOPATHOLOGY LEVEL: PGY2, PGY4, PGY5 The 1st block in PGY2 is an introductory in nature and is followed by two more blocks in PGY-4 (please, see core rotation for PGY4 below) and
More information